Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Prophylaxis and treatment of deep vein thrombosis (DVT),Prophylaxis and treatment of pulmonary embolism (PE),Anticoagulation for atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, myocardial infarction),Anticoagulation in extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Adult: IV bolus 5,000 units followed by continuous IV infusion at 1,000 units/hour (25,000-40,000 units/24h) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is dose-dependent: 0.5–1.5 hours after intravenous administration of 100 U/kg, increasing to 1.5–2.5 hours after 200 U/kg, and up to 3–6 hours after 400 U/kg. Clinically, the anticoagulant effect (a PTT) has a half-life of approximately 1–2 hours, and this is used for dosing adjustments.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Heparin is primarily cleared via the reticuloendothelial system and undergoes desulfation and depolymerization. A portion is excreted unchanged in urine.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: Heparin is primarily cleared by the reticuloendothelial system and the liver via desulfation and depolymerization, with metabolites excreted in urine. Only about 50% of an administered dose is excreted unchanged in urine at therapeutic doses; the remainder is metabolized. Biliary/fecal excretion is minimal.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Heparin binds extensively to various plasma proteins, including antithrombin III (high affinity), albumin, and other proteins. Overall protein binding is approximately 95%.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.06–0.07 L/kg (low, as heparin is largely confined to the intravascular space).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Subcutaneous: approximately 30–40% (low due to poor absorption and metabolism at injection site). Intravenous: 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific GFR-based dose adjustment required; monitor a PTT. In severe renal impairment (Cr Cl <30 m L/min), reduce infusion rate by 20-50% and monitor anti-Xa levels.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50% with close a PTT monitoring. Child-Pugh Class C: Avoid or use with extreme caution; reduce dose by 50-75%.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
IV bolus: 50-100 units/kg, then continuous IV infusion: 15-25 units/kg/hour. Titrate to a PTT 60-85 seconds or anti-Xa 0.3-0.7 units/m L.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients may have reduced clearance; use lower initial infusion rates (e.g., 750 units/hour) and monitor a PTT frequently. Start with 50% of the usual bolus dose in patients >70 years.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Heparin is not intended for intramuscular use due to risk of hematoma. Monitor for signs of bleeding, especially in patients with risk factors. Epidural or spinal hematomas may occur with concurrent neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis.
None.
Risk of hemorrhage: monitor coagulation parameters (a PTT) and adjust dose accordingly.,Heparin-induced thrombocytopenia (HIT): monitor platelet counts; discontinue if HIT suspected.,Hyperkalemia: heparin suppresses aldosterone synthesis; monitor potassium in high-risk patients.,Osteoporosis with long-term use ( >3 months).,Use with caution in patients with severe hepatic or renal impairment, uncontrolled hypertension, or history of gastrointestinal ulcers.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Active major bleeding (e.g., intracranial, gastrointestinal, retroperitoneal),History of heparin-induced thrombocytopenia (HIT),Severe thrombocytopenia (platelet count <100,000/µL),Hypersensitivity to heparin or porcine products,Known coagulation disorders (e.g., hemophilia, von Willebrand disease),Inability to perform appropriate coagulation monitoring (e.g., a PTT)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions. However, avoid excessive alcohol consumption as it may increase bleeding risk. Vitamin K-rich foods (e.g., leafy greens) do not affect heparin's anticoagulant effect, in contrast to warfarin.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Heparin is not known to cross the placenta due to its high molecular weight and negative charge, and is not associated with fetal teratogenicity. First trimester: No increased risk of major malformations. Second and third trimesters: No known teratogenic effects; use for treatment or prevention of thrombosis is considered safe. Risk of maternal hemorrhage and placental abruption exists with overdose.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Heparin is not excreted into breast milk due to its high molecular weight and negative charge, making it compatible with breastfeeding. M/P ratio is not applicable as it is undetectable in milk.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy is associated with increased plasma volume, renal clearance, and heparin-binding proteins, which may reduce heparin efficacy. Dose adjustment is often required: a PTT monitoring is mandatory, and doses are typically increased (up to 30-50% higher) to maintain therapeutic levels. Weight-based dosing should account for actual body weight. Postpartum, doses may need reduction due to normalization of clearance.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Use actual body weight for dosing; check a PTT 6 hours after initiation and after dose changes; monitor platelet count for heparin-induced thrombocytopenia (HIT); avoid intramuscular injections during therapy. Protamine sulfate (1 mg per 100 units heparin) reverses effects. For I. V. flushes, use preservative-free formulation when possible.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any unusual bleeding or bruising immediately.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed.,Inform all healthcare providers (including dentists) that you are on heparin.,Do not take any new medications without consulting your doctor.,Seek medical help if you experience signs of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Adult: IV bolus 5,000 units followed by continuous IV infusion at 1,000 units/hour (25,000-40,000 units/24h) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin is not known to cross the placenta due to its high molecular weight and negative charge, and is not associated with fetal teratogenicity. First trimester: No increased risk. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.